Botulinum-A Toxin: Solo Treatment for Neuropathic Noncompliant Bladder

Journal of Urology

Volumn 178, Issue 6, 2007, Pages 2593-2598

  Neel, Khalid Fouda ^a   Soliman, Sherif ^a   Salem, Mahmoud ^a   Seida, Mohammed ^a   Al Hazmi, Hamdan ^a   Khatab, Amenah ^a  

^a Department of Surgery   (Saudi Arabia)

Author keywords

botulinum toxin type A; neurogenic; urinary bladder

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN;

ARTICLE; BLADDER CAPACITY; BLADDER DISEASE; BLADDER PRESSURE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DETRUSOR MUSCLE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MALE; NEUROPATHIC BLADDER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; URODYNAMICS;

ADMINISTRATION, INTRAVESICAL; BOTULINUM TOXIN TYPE A; CHILD; CHILD, PRESCHOOL; CYSTOSCOPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENINGOCELE; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URODYNAMICS;

EID: 35748982091     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.08.032     Document Type: Article

References (18)

1. Leippold T., Reitz A., and Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44 (2003) 165
2. Aoki K.R. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 248 (2001) 3
3. Schantz E.J., and Johnson E.A. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 40 (1997) 317
4. Scott A.B., Rosenbaum A., and Collins C.C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12 (1973) 924
5. Scott A.B. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 79 (1981) 734
6. Dykstra D.D., Sidi A.A., Scott A.B., Pagel J.M., and Goldish G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139 (1988) 919
7. Chuang Y.C., Chiang P.H., Yoshimura N., De Miguel F., and Chancellor M.B. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 98 (2006) 1033
8. Calderon-Gonzalez R., Calderon-Sepulveda R., Rincon-Reyes M., Garcia-Ramirez J., and Mino-Arango E. Botulinum toxin A in management of cerebral palsy. Pediatr Neurol 10 (1994) 284
9. Hernandez R.D., Hurwitz R.S., Foote J.E., Zimmern P.E., and Leach G.E. Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele. J Urol 152 (1994) 1582
10. Schulte-Baukloh H., Michael T., Schobert J., Stolze T., and Knispel H.H. Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59 (2002) 325
11. Schulte-Baukloh H., Michael T., Sturzebecher B., and Knispel H.H. Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44 (2003) 139
12. Riccabona M., Koen M., Schindler M., Goedele B., Pycha A., Lusuardi L., et al. Botulinum-A toxin injection into the detrusor: a safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171 (2004) 845
13. Kajbafzadeh A.M., Moosavi S., Tajik P., Arshadi H., Payabvash S., Salmasi A., et al. Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology 68 (2006) 1091
14. McGuire E.J., Woodside J.R., Borden T.A., and Weiss R.M. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 126 (1981) 205
15. Bauer S.B., Hallett M., Khoshbin S., Lebowitz R.L., Winston K.R., Gibson S., et al. Predictive value of urodynamic evaluation in newborns with myelodysplasia. JAMA 252 (1984) 650
16. Hafez A.T., McLorie G., Gilday D., Laudenberg B., Upadhyay J., Bagli D., et al. Long-term evaluation of metabolic profile and bone mineral density after ileocystoplasty in children. J Urol 170 (2003) 1639
17. Palmer L.S., Zebold K., Firlit C.F., and Kaplan W.E. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol 157 (1997) 638
18. Reitz A., Stohrer M., Kramer G., Del Popolo G., Chartier-Kastler E., Pannek J., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 (2004) 510